PDE

Pattern to Present in London, UK at the LSX World Congress

Retrieved on: 
Wednesday, April 17, 2024
Congress, Investment, AI, Research, Medtech, Business, Pattern, LSX, Cancer, PDE, Management

REDMOND, Wash., April 16, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will be presenting at the LSX World Congress which will take place in London, UK on April 29-30, 2024, at the Business Design Center.

Key Points: 
  • REDMOND, Wash., April 16, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will be presenting at the LSX World Congress which will take place in London, UK on April 29-30, 2024, at the Business Design Center.
  • LSX World Congress is the leading partnering, strategy, and investment event in Europe, with a strong focus on one-to-one partnering.
  • “Pattern is a pioneer in finding novel patterns in complex data that cannot be discovered using other techniques or tools,” commented Mr. Anderson.
  • Pattern is optimally positioned to leverage the expertise of our Pattern Discovery Engine™ (PDE) into the next worlds of trustworthy, transparent computing.

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Retrieved on: 
Thursday, March 14, 2024
Lung cancer, TME, 5T4, Assistant, Patient, Lung, Tumor microenvironment, PM, PBMC, CD3, Neoplasm, NK, Escape Room, Drug resistance, PDE, Vaccine

REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.

Key Points: 
  • REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform.
  • “Our tribody platform is differentiated with its dual engagers including its NK cell engager having a dual mechanism of action, in addition to the conditionally activated T cell engager.
  • We are excited about the potential of this platform to produce a pipeline of promising drug candidates that can be effective across numerous solid cancer tumors,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • Purple Biotech’s cleavable capping technology confines the compound’s therapeutic activity to the local tumor micro environment (TME), which increases the anticipated therapeutic window in patients.

Pattern to Attend NVIDIA’s GTC 2024 Conference

Retrieved on: 
Monday, March 11, 2024
Inception, Cancer, Drug discovery, Conference, Pattern, Intuition, PDE, Artificial intelligence, Research

REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.

Key Points: 
  • REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.
  • During the conference, Pattern will conduct one-on-one meetings with investors and potential partners, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • To schedule a meeting with Pattern, please contact Pattern’s Executive Vice President of Special Projects, Denyse Hudson, at [email protected] .
  • Mr. Anderson commented, “Pattern uses proprietary pattern discovery techniques to perform high-dimensional data analytics in any field with significant data complexity.

Virsys12 Boosts Healthcare Operations with New Provider Data Management Features

Retrieved on: 
Tuesday, February 27, 2024
Consensus, Directory, Completeness, CMS, Record, Data management, NetworkManager, Government, CAQH, SAAS, PRS, ViVe, NPI, TIN, Salesforce, Data Age, PDE

BRENTWOOD, Tenn., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Virsys12, a leading provider of solutions for provider network management and ongoing provider data management and directory updates, today announced at the ViVE conference in Los Angeles, CA, new features in its flagship SAAS applications, V12 Network and V12 Provider Data Engine (PDE). With its robust and scalable platform, Virsys12 continues to empower healthcare organizations to eliminate inefficiencies in their provider data management and workflow processes.

Key Points: 
  • BRENTWOOD, Tenn., Feb. 27, 2024 /PRNewswire-PRWeb/ -- Virsys12 , a leading provider of solutions for provider network management and ongoing provider data management and directory updates, today announced at the ViVE conference in Los Angeles, CA, new features in its flagship SAAS applications, V12 Network and V12 Provider Data Engine (PDE) .
  • With its robust and scalable platform, Virsys12 continues to empower healthcare organizations to eliminate inefficiencies in their provider data management and workflow processes.
  • Custom Data Field Mapping: Update provider data based on "groupings," increase data auditability, and implement manual or automatic data override functionality.
  • "This application processes data from various provider data sources, including provider demographics, provider taxonomies and specialties, and practicing location (both master address location data and practitioner address data).

$10 million Artificial Intelligence Mathematical Olympiad Prize appoints advisory committee members

Retrieved on: 
Wednesday, February 7, 2024
Tao, XTX, University College London, University, Machine learning, UCLA, Sequoia, Female, Engineer, Marshall Scholarship, United Kingdom Mathematics Trust, W. W. Rouse Ball, Breakthrough Prize, Principle, Silver, Sequoia Capital, Advisory Committee, Fields Medal, Gold, Salesforce, Game theory, Carnegie Mellon University, Artificial intelligence, Salem Prize, Trinity College, Royal Society, Research, Scientist, Princeton University, Crafoord, Doctor of Philosophy, Combinatorics, MacArthur Fellows Program, XTX Markets, Cambridge University Press, AI, PDE, Education, Diffeomorphism, MIT, Timothy Gowers, Prize, Management

LONDON, Feb. 7, 2024 /PRNewswire/ -- XTX Markets' newly created Artificial Intelligence Mathematical Olympiad Prize ('AIMO Prize') is a $10mn challenge fund designed to spur the creation of a publicly shared AI model capable of winning a gold medal in the International Mathematical Olympiad (IMO).

Key Points: 
  • Fields Medallists Timothy Gowers and Terence Tao appointed to the Advisory Committee for the Artificial Intelligence Mathematical Olympiad Prize, alongside Po-Shen Loh, Dan Roberts and Geoff Smith.
  • The AIMO Advisory Committee will support the development of the AIMO Prize, including advising on appropriate protocols and technical aspects, and designing the various competitions and prizes.
  • It will be important to experiment with multiple approaches to this goal, and to benchmark the performance of each of them.
  • Eoghan Flanagan, Director of the AIMO Prize, commented:
    "We are delighted to welcome such esteemed members of the mathematical community to the advisory committee of the AIMO Prize.

$10 million Artificial Intelligence Mathematical Olympiad Prize appoints advisory committee members

Retrieved on: 
Wednesday, February 7, 2024
Tao, XTX, University College London, University, Machine learning, UCLA, Sequoia, Female, Engineer, Marshall Scholarship, United Kingdom Mathematics Trust, W. W. Rouse Ball, Breakthrough Prize, Principle, Silver, Sequoia Capital, Advisory Committee, Fields Medal, Gold, Salesforce, Game theory, Artificial intelligence, Salem Prize, Trinity College, Royal Society, Research, Scientist, Princeton University, Crafoord, Doctor of Philosophy, Combinatorics, MacArthur Fellows Program, XTX Markets, Cambridge University Press, AI, PDE, Education, Diffeomorphism, MIT, Timothy Gowers, Prize, Management

LONDON, Feb. 7, 2024 /PRNewswire/ -- XTX Markets' newly created Artificial Intelligence Mathematical Olympiad Prize ('AIMO Prize') is a $10mn challenge fund designed to spur the creation of a publicly shared AI model capable of winning a gold medal in the International Mathematical Olympiad (IMO).

Key Points: 
  • Fields Medallists Timothy Gowers and Terence Tao appointed to the Advisory Committee for the Artificial Intelligence Mathematical Olympiad Prize, alongside Po-Shen Loh, Dan Roberts and Geoff Smith.
  • The AIMO Advisory Committee will support the development of the AIMO Prize, including advising on appropriate protocols and technical aspects, and designing the various competitions and prizes.
  • It will be important to experiment with multiple approaches to this goal, and to benchmark the performance of each of them.
  • Eoghan Flanagan, Director of the AIMO Prize, commented:
    "We are delighted to welcome such esteemed members of the mathematical community to the advisory committee of the AIMO Prize.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Outreach Announces Abhijit Mitra as President of Product and Technology

Retrieved on: 
Thursday, October 26, 2023
Abhijit, CG Power and Industrial Solutions, GTM, PDE, Magic Quadrant, Productivity-improving technologies, SAP, ServiceNow, Customer service, Mitra, Unleash, Software as a service, Sales, Engineering, Outreach, Oracle

SEATTLE, Oct. 26, 2023 /PRNewswire/ -- Outreach, the leading AI Sales Platform helping revenue organizations create better pipeline and close more deals, today announced engineering veteran Abhijit Mitra as its new President of Product and Technology. Mitra will lead the Product, Design, and Engineering (PDE) organization.

Key Points: 
  • Product and Engineering Veteran to Lead Sales Execution Platform Expansion Across New Verticals and Personas, Continue Enterprise Growth
    SEATTLE, Oct. 26, 2023 /PRNewswire/ -- Outreach , the leading AI Sales Platform helping revenue organizations create better pipeline and close more deals, today announced engineering veteran Abhijit Mitra as its new President of Product and Technology.
  • Mitra will lead the Product, Design, and Engineering (PDE) organization.
  • As a business and customer-oriented leader, Abhijit will work closely with David Ruggiero, Outreach President of GTM, to bring these new innovations to market.
  • "When searching for our Product and Technology President, we wanted someone with visionary excellence to lead Outreach in our platform journey," said Manny Medina, CEO and Co-founder of Outreach.

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Retrieved on: 
Tuesday, October 3, 2023
Ethos, Linda, Necrotizing meningoencephalitis, Seizure, Human, Survival, Brain, Research, Brain damage, Inflammation, Multiple sclerosis, Doctor of Philosophy, Neck, Microsoft Exchange Server, Back pain, Discovery, HIV disease progression rates, T-cell receptor excision circles, SAN, Lethargy, DSM-IV codes, Dog, Blood, Pet, Simons, Steroid, Genetic testing, Cat, Diagnosis, B cell, Therapy, PDE, Phenotype, Encephalitis, DVM, NME, Gallant, Disease, Neurology, Pharmaceutical industry, Medical imaging

Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.

Key Points: 
  • Within 24 hours, Walter was diagnosed with pug dog encephalitis (PDE), a common name for necrotizing meningoencephalitis (NME) because it occurs most commonly in that breed.
  • Despite aggressive therapy with steroids, immunosuppressants, and anti-seizure medications, Walter died within 24 hours of his diagnosis.
  • In this third study in the program, Ethos Discovery and Gallant Therapeutics are investigating treatment with Gallant’s MSCs in pugs previously screened for NME.
  • To learn more about enrolling your pug in the study, please visit: https://www.ethosdiscovery.org/clinical-study/necrotizing-meningoencepha....